S&P 500
7,500.60
-0.32%
Dow Jones
51,631.30
-0.25%
Nasdaq 100
30,362.30
-0.39%
Russell 2000
2,964.43
-0.46%
FTSE 100
10,391.60
-0.28%
Nikkei 225
71,634.70
-0.47%

Investing

IMRX logo Immuneering : IMRX

IMRX

Stock Data

$4.41

Change up

$0.00 (0.00%)

Asset Type

Common Stock

Exchange

NASDAQ

Currency

USD

Country

USA

Sector

HEALTHCARE

Industry

BIOTECHNOLOGY

Immuneering Corp Class A is a pioneering force in the fight against cancer, focusing on creating medicines for a wide range of cancer patients. With its flagship products, IMM-1-104 and IMM-6-415, the company targets various cancers including pancreatic, melanoma, colorectal, and non-small cell lung cancer, specifically those caused by RAS and/or RAF mutations. Founded in 2008 and headquartered in Cambridge, Massachusetts, Immuneering is at the forefront of clinical-stage oncology research, aiming to bring innovative treatments from the lab to the patient.

All Immuneering Articles

3 Articles